Drug Approval | December 31, 2022
InnoCare get approval of Tafasitamab with Lenalidomide for the treatment of refractory diffuse large B-Cell lymphoma in Hong Kong
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
_256_275.jpg)